Medha D Joshi, Ph.D.

Glendale, AZ

Home / Academics / Medha D Joshi, Ph.D.


Dr. Medha D Joshi is an Associate Professor in Pharmaceutical Sciences at Midwestern University’s Chicago College of Pharmacy. Dr Joshi has expertise in lipid based drug delivery systems including solid lipid nanoparticles (SLN), micro emulsions, self emulsifying drug delivery systems (SMEDDs), nanosuspensions, and liposomes, targeted drug delivery etc. Her research program at Midwestern university is focused on application of nanoparticulate targeted delivery a) to neurogenetic peptides for their delivery to the blood brain barrier and b) reduction of maternal-fetal toxicity of drugs across the placental barrier. She has more than 30 peer reviewed research articles, 2 patents and 3 book chapters to her credit. She has been a Principle Investigator and co-investigator on several intramural and extramural grants such as Alzheimer’s Drug Discovery foundation, NIH AREA grant etc.


Glendale, AZ

College of Graduate Studies - AZ
College of Pharmacy
Glendale Campus

Pharmaceutical Sciences


Send Me
a Message


Institute of Chemical Technology (UDCT)
India | 2006 | Ph.D.
Pune University
India | 2002 | M.S.
Pune University
India | 2000 | B.Pharm.

Courses Taught

  • PSCIG 1540: Phamaceutical Calculations
  • PSCIG 1541: Phamaceutics-I


1.     Design and development of a clinically acceptable, long circulating liposomal delivery system for IRL-1620 and its evaluation in cerebral ischemia rat models.

In the present study, we propose to test the hypothesis that polyethylene glycol (PEG)ylated liposomal delivery of ETB receptor agonist, IRL-1620 may be efficacious in the treatment of cerebral ischemia. PEGylated liposomes encapsulating IRL-1620 with and without a cationic charge and "targeted" PEGylated liposomes to the transferrin receptor on the brain endothelium will be formulated. Further, these nanocarriers will be tested for their neuroprotection efficiency on pheochromocytoma cells in vitro. The liposomal nanocarriers of IRL-1620 will be elucidated for their ability to accumulate in the brain and amelioration of infarct volume, neurological deficit and motor functions in vivo, in a cerebral ischemia rat model. This study will help in generating the proof of concept that by delivering IRL-1620 in long circulating PEGylated liposomal nanocarriers, higher efficiency in dose and dosing frequency can be achieved. This will have a tremendous clinical significance in the management of stroke, wherein restoration of blood flow and attenuation of secondary damage to the penumbral area by IRL-1620 will be achieved for a longer period of time with fewer side effects and at a higher efficacy.

2. HPLC/LCMS assay development for analytical estimation  of actives from biological matrices

3. Classifying and overcoming fetal and maternal vancomycin-induced kidney injury: a pregnant rat model to understand and a new formulation to circumvent  

Approximately 90% of pregnant women and their fetuses are exposed to at least one medication during the pregnancy. The FDA previously classified the safety of medications in pregnancy as “A,B,C,D, or X” (X=teratogenic/avoid) according to their teratogenicity potentials; however, these classifications have been removed. Hence, clinicians are forced now more than ever to rely on primary medical literature for the safety of drugs during pregnancy. Vancomycin is a commonly used antibiotic during pregnancy for the treatment of severe sepsis and a candidate drug for our study. Although vancomycin was previously FDA classified as pregnancy category B, emerging data suggest kidney damage in adults. Further, data suggests that vancomycin crosses the placental barrier, though early toxicity studies have not employed the more sensitive assessments of kidney function necessary to classify damage, thus less is known about vancomycin’s toxicity to the fetus. Because of the common use and importance of vancomycin for life-threatening infections to the mother, vancomycin serves as a candidate drug for 1) improved understanding of the relationship between drug exposure and fetal kidney toxicity and 2) molecular modification to retain efficacy while circumventing toxicity to the mother and fetus.

AIM1: Quantify the relationship between fetal vancomycin exposure and kidney injury to rat pups

Details: Methodologies that were not previously studied, such as the analysis of Kidney Injury 1 molecule, are highly sensitive and specific for vancomycin kidney injury. Additionally, we will measure vancomycin concentrations in the rat pup kidneys to see if accumulation occurs. 

AIM2: Develop and characterize a liposomal formulation of vancomycin designed to minimize transplacental transfer

Details: The parent compound will be encapsulated in liposomal core in order to minimize transplacental crossing to the fetus and renal tubular transit for the mother, thereby circumventing injury for both fetus and mother.


  1. Joshi M and Patravale V (2006) Formulation and evaluation of Nanostructured Lipid Carrier (NLC)-based gel of Valdecoxib. Drug Dev Ind Pharm 32:911-918 PubMed PMID: 16954103.
  2. Shah K, Date A, Joshi M and Patravale V (2007) Solid lipid nanoparticles (SLN) of tretinoin: potential in topical delivery. Int J Pharm 345:163-171 PubMed PMID: 20055085.
  3. Date A, Joshi M and Patravale V (2007) Parasitic diseases: Liposomes and polymeric nanoparticles versus lipid nanoparticles. Adv Drug Deliv Rev 59:505-521 PubMed PMID: 17574295.
  4. Joshi M, Pathak S, Sharma S and Patravale V (2008) Design and in vivo pharmacodynamic evaluation of nanostructured lipid carriers for parenteral delivery of artemether: Nanoject. Int J Pharm 364:119-126 doi: 10.1016/j.ijpharm.2008.07.032. PubMed PMID: 18765274.
  5. Joshi M, Pathak S, Sharma S and Patravale V (2008) Solid microemulsion preconcentrate (NanOsorb) of artemether for effective treatment of malaria. Int J Pharm 362:172-178 doi: 10.1016/j.ijpharm.2008.06.012. PubMed PMID: 18611435.
  6. Joshi M and Patravale V (2008) Nanostructured lipid carrier (NLC) based gel of celecoxib. Int J Pharm 346:124-132 PubMed PMID: 17651933.
  7. Shah K, Joshi M and Patravale V (2009) Biocompatible microemulsions for fabrication of glyceryl monostearate solid lipid nanoparticles (SLN) of tretinoin. J Biomed Nanotechnol 5:396-400 doi: 10.1016/j.ijpharm.2008.06.012. PubMed PMID: 18611435.
  8. Joshi M and Muller R (2009) Lipid nanoparticles for parenteral delivery of actives. Eur J Pharm Biopharm 71:161-172 doi: 10.1016/j.ejpb.2008.09.003. PubMed PMID: 18824097.
  9. Joshi M, Unger W, van Beelen A, Bruijns S, Litjens M, van Bloois L, Kalay H, van Kooyk Y and Storm G (2011) DC-SIGN mediated antigen-targeting using glycan-modified liposomes: formulation considerations. Int J Pharm 416:426-432 doi: 10.1016/j.ijpharm.2011.02.055. PubMed PMID: 21371544 .
  10. Joshi M, Unger W, Storm G, van Kooyk Y and Mastrobattista E (2012) Targeting tumor antigens to dendritic cells using particulate carriers. Journal of controlled release 161:25-37 doi: 10.1016/j.jconrel.2012.05.010. PubMed PMID: 22580109.
  11. Patil S, Joshi M, Pathak S, Sharma S and Patravale V (2012) Intravenous beta-artemether formulation (ARM NLC) as a superior alternative to commercial artesunate formulation. The Journal of antimicrobial chemotherapy 67:2713-2716 doi: 10.1093/jac/dks293. PubMed PMID: 22899802.
  12. Unger W, van Beelen A, Bruijns S, Joshi M, Fehres C, van Bloois L, Verstege M, Ambrosini M, Kalay H, Nazmi K, Bolscher J, Hooijberg E, de Gruijl T, Storm G and van Kooyk Y (2012) Glycan-modified liposomes boost CD4+ and CD8+ T-cell responses by targeting DC-SIGN on dendritic cells. Journal of controlled release 160:88-95 doi: 10.1016/j.jconrel.2012.02.007. PubMed PMID: 22366522.
  13. Prabhu P, Patravale V and Joshi M (2012) Nanocarriers for Effective Topical Delivery of Anti-Infectives. Current Nanoscience 8:491-503.
  14. Mehendale R, Joshi M and Patravale VB (2013) Nanomedicines for treatment of viral diseases. Critical reviews in therapeutic drug carrier systems 30:1-49 PubMed PMID: 23510109.
  15. Jain S, Basu H, Prabhu P, Soni U, Joshi M, Mathur, D, Patravale V, Pathak and S Sharma S (2014) Parasite Impairment by Targeting Plasmodium-Infected RBCs Using Glyceryl-dilaurate Nanostructured Lipid Carriers. Biomaterials 35: 6636-6645 doi: 10.1016/j.biomaterials.2014.04.058. PubMed PMID: 24818881.
  16. Oesterling B, Gulati A and Joshi M (2014) Nanocarrier Based Approaches for Treatment and Detection of Alzheimer's disease. Journal of Nanoscience and Nanotechnology 14:137-156 PubMed PMID: 24730256.
  17. Li W, Joshi M, Singhania S, Ramsey K, Murthy A (2014) Peptide Vaccine: Progress and Challenges, published in the special issue: Peptide Vaccine, Vaccines 2, 515-536 doi: 10.3390/vaccines2030515.PubMed PMID: 26344743; PubMed Central PMCID: PMC4494216.
  18. Kain V, Ingle K, Prabhu S, Serhan C, Joshi M, and Halade G (2015) Resolvin D1 activates inflammation resolving response at splenic and ventricular site following myocardial infarction leading to improved ventricular function, Journal of Molecular and Cellular Cardiology 84: 24-35, doi: 10.1016/j.yjmcc.2015.04.003. Epub 2015 Apr 11. PubMed PMID: 25870158; PubMed Central PMCID: PMC4468047.
  19. Prabhu R, Patravale V and Joshi M (2015) Polymeric nanoparticles for targeted treatment in oncology: Current insights. International Journal of Nanomedicine, 10, 1001-1018 doi: 10.2147/IJN.S56932. Review. PubMed PMID: 25678788; PubMed Central PMCID: PMC4324541.
  20. Joshi M, Oesterling B, Wu C, Gwizdz N, Pais G, Briyal S and Gulati A (2016) Evaluation of liposomal nanocarriers loaded with ETB receptor agonist, IRL-1620, using cell based assays, Neuroscience, 312, 141-152 doi: 10.1016/j.neuroscience.2015.11.016. PubMed PMID: 26592721.
  21. Joshi M, Park G, Pichlik J, Patel K and Patel R (2017) In vitro evaluation of bortezomib encapsulated in cationic and C6-ceramide liposomes, Journal of Pharmaceutical Sciences and Pharmacology, 3, 1-9.
  22. Joshi M, O’Donnell J, Venkatesan N, Chang J, Nguyen H, Rhodes N, Pais G, Chapman R, Griffin B and Scheetz M, (2017) High-performance liquid chromatography (HPLC) method for rich pharmacokinetic sampling schemes in translational rat toxicity models with vancomycin, Clinical and Translational Science, open access, Nov;10(6):496-502. doi 10.1111/cts.12484 doi: 10.1111/cts.12484. Epub 2017 Jul 4. PubMed PMID: 28675684; PubMed Central PMCID: PMC5698807.
  23. O'Donnell J, Rhodes N J, Lodise T, Prozialeck W, Miglis C M, Joshi M, Natarajan V, Pais G, Cluff C,  Lamar P, Briyal S, Zhan Z, Day J.Z., Gulati A., Scheetz M. H,.(2017) 24-Hour Pharmacokinetic Relationships for Vancomycin and Novel Urinary Biomarkers of Acute Kidney Injury Antimicrob Agents Chemother. 2017 Oct 24;61(11). pii: e00416-17. doi: 10.1128/AAC.00416-17. Print 2017 Nov. PubMed PMID: 28807910; PubMed Central PMCID: PMC5655072.
  24. O’Donnell J N, Rhodes N J, Miglis C, Catovic L, Liu J, Cluff C, Pais G, Avedissian S, Joshi M, Griffin B, Prozialeck W, Gulati A, Lodise T P, Scheetz M H (2017) Doses, durations, and gender predict vancomycin-induced kidney injury in pre-clinical studies, International Journal of Antimicrobial Agents, pii: S0924-8579(17)30304-7. doi: 10.1016/j.ijantimicag.2017.08.012. PubMed PMID: 28803934.
  25. Schlich M, Sinico C, Valenti D, Gulati A, Joshi M, Meli V, Murgias S, Xanthos T (2019) Towards long-acting adrenaline for cardiopulmonary resuscitation: production and characterization of a liposomal formulation, International Journal of Pharmaceutics, 557, .105-111; PMID: 30586629
  26. Avedissian S, Pais G, Joshi, M, Rhodes N, Scheetz M A Translational Pharmacokinetic Rat Model of Cerebral Spinal Fluid (CSF) and Plasma Concentrations of Cefepime mSphere (2019) 4 (1) e00595-18; DOI: 10.1128/mSphere.00595-18.
  27. Avedissian S N, Pais G, O’Donnell J N, Lodise T P, Liu J, Prozialeck W, Joshi M, Lamar P, Becher L, Gulati A, Hope W, Scheetz M H (2019) Twenty-four hour pharmacokinetic relationships for intravenous vancomycin and novel urinary biomarkers of acute kidney injury in a rat model, Journal of Antimicrobial Chemotherapy, 74(8):2326-2334. doi: 10.1093/jac/dkz167.
  28. Joshi M, Pais GM, Chang J, Hlukhenka K, Avedissian SN, Gulati A, Prozialeck W, Lamar PC, Zhang Z, Scheetz MH, Griffin B (2019) Evaluation of Fetal and Maternal Vancomycin-Induced Kidney Injury during Pregnancy in a Rat Model. Manuscript revision submitted to Antimicrobial Agents and Chemotherapy 63(10). pii: e00761-19. doi: 10.1128/AAC.00761-19
  29. Verdone M., Joshi M, Bodenstine T. M., Green J., Lynch S., Gettig J. P., Fjortoft N., (2020) Impact of an Online, Self-Directed Pre-Pharmacy Bridging Course On Students’ Academic Performance, American Journal of Pharmaceutical Education, 84 (1)


  1. Member, American Association of Pharmaceutical Scientists (AAPS)
  2. Member, Controlled release Society (CRS)
  3. Member, American Nano Society, USA
  4. Member, American association of colleges of pharmacy (AACP)
  5. Member, Chicagoland Pharmaceutical Discussion Group
  6. Life Member, Indian Pharmaceutical Association (IPA), Mumbai, India
  7. Life Member, Indian Women Scientist Association, Mumbai, India


  1. Research faculty for NIH grant#5664 R15 2014-2017“Elucidation of an informed drug dose dosing scheme to minimize kidney injury” Marc Scheetz (PI) Medha Joshi (Research Faculty) 
  2. Co- investigator for a grant from the Alzheimer’s Drug Discovery foundation for a grant proposal "Nanocarrier formulation of ETB receptor agonist, IRL-1620, for the treatment of Alzheimer's disease" Anil Gulati (PI), Medha Joshi (Co-I) for the year 2012-2013. 
  3. Co- investigator for a grant from Care Foundation for $12,500 “Defining the Link between Cefepime Exposure and Effect in Canine Pneumonia: A Two-Way Bridge Serving Dogs and Humans” for Jan 2016-Dec 2017. Marc Scheetz (PI) Medha Joshi (Co-I) 


  1. MWU Chicago College of Pharmacy, PS-1 class teacher of the year 2017-2018 award by class of 2021, runner up 2017, 2019, 2020
  2. Scholarship conferred by Deutscher Akademischer Austausch Dienst (DAAD) i.e. German Academic Exchange Service to pursue Post doctoral research studies at Free University of Berlin
  3. Awarded best poster award for the presentation entitled ‘Hydrophobic nanostructured lipid carriers as novel modification for dermal application’ at European Workshop on Particulate Systems, Berlin, May 30-31, 2008
  4. Awarded best poster award for the presentation entitled ‘Nanoject: Nanostructured Lipid Nanocarrier based intravenous injection of Artemether’ at the 7th International Symposium on Advances in Technology and Business Potential of New Drug Delivery Systems, 13-14 February, 2007, Mumbai, India
  5. Mahindra Search for Talent Scholarship for standing first at the M. Pharmacy Examination, January 2002.
  6. Young scientist travel grant by Council of Scientific and Industrial Research (CSIR), Ministry of Human Resource and Development, Government of India to attend and present posters at 32nd Annual Meeting & Exposition of the Controlled Release Society, Miami Florida, USA, June 18-22, 2005
  7. Travel grant by Shalaks Pharmaceuticals, New Delhi to attend and present posters at 32nd Annual Meeting & Exposition of the Controlled Release Society, Miami Florida, USA, June 18-22, 2005.
  8. Two times University ranker 1st in Pune University at M. pharmacy level 2002 and 10th in Pune University at B. Pharmacy 2000.
  9. Biography appeared in Stanford who’s who and Marquis who’s who in the year 2011.
  10. PS-1 Teacher of the year awarded by class of 2021 at Midwestern University, Chicago College of Pharmacy
  11. 2020 AAPS Best Abstract Award, Abstract entitled “In Vitro Evaluation of Nephrotoxicity and Permeation Studies on Vancomycin Loaded Liposomes” was among the top 10% of abstracts based on high ratings by AAPS Abstract Screening Committee.